Identification of BACE2 as an avid -amyloid-degrading protease

Samer O. Abdul-Hay, Tomoko Sahara, Melinda McBride, Dongcheul Kang, Malcolm A. Leissring

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Proteases that degrade the amyloid β-protein (Aβ) have emerged as key players in the etiology and potential treatment of Alzheimers disease (AD), but it is unlikely that all such proteases have been identified. To discover new A-degrading proteases (AβDPs), we conducted an unbiased, genome-scale, functional cDNA screen designed to identify proteases capable of lowering net Aβ levels produced by cells, which were subsequently characterized for Aβ-degrading activity using an array of downstream assays. Results: The top hit emerging from the screen was β-site amyloid precursor protein-cleaving enzyme 2 (BACE2), a rather unexpected finding given the well-established role of its close homolog, BACE1, in the production of Aβ. BACE2 is known to be capable of lowering Aβ levels via non-amyloidogenic processing of APP. However, in vitro, BACE2 was also found to be a particularly avid ADP, with a catalytic efficiency exceeding all known AβDPs except insulin-degrading enzyme (IDE). BACE1 was also found to degrade Aβ, albeit ∼150-fold less efficiently than BACE2. A is cleaved by BACE2 at three peptide bondsPhe19-Phe20, Phe20-Ala21, and Leu34-Met35with the latter cleavage site being the initial and principal one. BACE2 overexpression in cultured cells was found to lower net A levels to a greater extent than multiple, well-established AβDPs, including neprilysin (NEP) and endothelin-converting enzyme-1 (ECE1), while showing comparable effectiveness to IDE. Conclusions: This study identifies a new functional role for BACE2 as a potent AβDP. Based on its high catalytic efficiency, its ability to degrade A intracellularly, and other characteristics, BACE2 represents a particulary strong therapeutic candidate for the treatment or prevention of AD.

Original languageEnglish (US)
Article number46
JournalMolecular Neurodegeneration
Volume7
Issue number1
DOIs
StatePublished - 2012

Fingerprint

Amyloid
Peptide Hydrolases
Insulysin
Alzheimer Disease
Efficiency
Serum Amyloid A Protein
Neprilysin
Aptitude
Amyloid beta-Protein Precursor
Cultured Cells
Complementary DNA
Genome
Peptides
Enzymes

Keywords

  • β-site APP-cleaving enzyme-1
  • -site APP-cleaving enzyme-2
  • Alzheimer disease
  • Amyloid-β-protein
  • Functional screen
  • Gene therapy
  • Protease
  • Proteolytic degradation

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Clinical Neurology
  • Molecular Biology

Cite this

Abdul-Hay, S. O., Sahara, T., McBride, M., Kang, D., & Leissring, M. A. (2012). Identification of BACE2 as an avid -amyloid-degrading protease. Molecular Neurodegeneration, 7(1), [46]. https://doi.org/10.1186/1750-1326-7-46

Identification of BACE2 as an avid -amyloid-degrading protease. / Abdul-Hay, Samer O.; Sahara, Tomoko; McBride, Melinda; Kang, Dongcheul; Leissring, Malcolm A.

In: Molecular Neurodegeneration, Vol. 7, No. 1, 46, 2012.

Research output: Contribution to journalArticle

Abdul-Hay, SO, Sahara, T, McBride, M, Kang, D & Leissring, MA 2012, 'Identification of BACE2 as an avid -amyloid-degrading protease', Molecular Neurodegeneration, vol. 7, no. 1, 46. https://doi.org/10.1186/1750-1326-7-46
Abdul-Hay, Samer O. ; Sahara, Tomoko ; McBride, Melinda ; Kang, Dongcheul ; Leissring, Malcolm A. / Identification of BACE2 as an avid -amyloid-degrading protease. In: Molecular Neurodegeneration. 2012 ; Vol. 7, No. 1.
@article{4f80eb29e0704b0f9bfdd5a22a4b45e1,
title = "Identification of BACE2 as an avid -amyloid-degrading protease",
abstract = "Background: Proteases that degrade the amyloid β-protein (Aβ) have emerged as key players in the etiology and potential treatment of Alzheimers disease (AD), but it is unlikely that all such proteases have been identified. To discover new A-degrading proteases (AβDPs), we conducted an unbiased, genome-scale, functional cDNA screen designed to identify proteases capable of lowering net Aβ levels produced by cells, which were subsequently characterized for Aβ-degrading activity using an array of downstream assays. Results: The top hit emerging from the screen was β-site amyloid precursor protein-cleaving enzyme 2 (BACE2), a rather unexpected finding given the well-established role of its close homolog, BACE1, in the production of Aβ. BACE2 is known to be capable of lowering Aβ levels via non-amyloidogenic processing of APP. However, in vitro, BACE2 was also found to be a particularly avid ADP, with a catalytic efficiency exceeding all known AβDPs except insulin-degrading enzyme (IDE). BACE1 was also found to degrade Aβ, albeit ∼150-fold less efficiently than BACE2. A is cleaved by BACE2 at three peptide bondsPhe19-Phe20, Phe20-Ala21, and Leu34-Met35with the latter cleavage site being the initial and principal one. BACE2 overexpression in cultured cells was found to lower net A levels to a greater extent than multiple, well-established AβDPs, including neprilysin (NEP) and endothelin-converting enzyme-1 (ECE1), while showing comparable effectiveness to IDE. Conclusions: This study identifies a new functional role for BACE2 as a potent AβDP. Based on its high catalytic efficiency, its ability to degrade A intracellularly, and other characteristics, BACE2 represents a particulary strong therapeutic candidate for the treatment or prevention of AD.",
keywords = "β-site APP-cleaving enzyme-1, -site APP-cleaving enzyme-2, Alzheimer disease, Amyloid-β-protein, Functional screen, Gene therapy, Protease, Proteolytic degradation",
author = "Abdul-Hay, {Samer O.} and Tomoko Sahara and Melinda McBride and Dongcheul Kang and Leissring, {Malcolm A.}",
year = "2012",
doi = "10.1186/1750-1326-7-46",
language = "English (US)",
volume = "7",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Identification of BACE2 as an avid -amyloid-degrading protease

AU - Abdul-Hay, Samer O.

AU - Sahara, Tomoko

AU - McBride, Melinda

AU - Kang, Dongcheul

AU - Leissring, Malcolm A.

PY - 2012

Y1 - 2012

N2 - Background: Proteases that degrade the amyloid β-protein (Aβ) have emerged as key players in the etiology and potential treatment of Alzheimers disease (AD), but it is unlikely that all such proteases have been identified. To discover new A-degrading proteases (AβDPs), we conducted an unbiased, genome-scale, functional cDNA screen designed to identify proteases capable of lowering net Aβ levels produced by cells, which were subsequently characterized for Aβ-degrading activity using an array of downstream assays. Results: The top hit emerging from the screen was β-site amyloid precursor protein-cleaving enzyme 2 (BACE2), a rather unexpected finding given the well-established role of its close homolog, BACE1, in the production of Aβ. BACE2 is known to be capable of lowering Aβ levels via non-amyloidogenic processing of APP. However, in vitro, BACE2 was also found to be a particularly avid ADP, with a catalytic efficiency exceeding all known AβDPs except insulin-degrading enzyme (IDE). BACE1 was also found to degrade Aβ, albeit ∼150-fold less efficiently than BACE2. A is cleaved by BACE2 at three peptide bondsPhe19-Phe20, Phe20-Ala21, and Leu34-Met35with the latter cleavage site being the initial and principal one. BACE2 overexpression in cultured cells was found to lower net A levels to a greater extent than multiple, well-established AβDPs, including neprilysin (NEP) and endothelin-converting enzyme-1 (ECE1), while showing comparable effectiveness to IDE. Conclusions: This study identifies a new functional role for BACE2 as a potent AβDP. Based on its high catalytic efficiency, its ability to degrade A intracellularly, and other characteristics, BACE2 represents a particulary strong therapeutic candidate for the treatment or prevention of AD.

AB - Background: Proteases that degrade the amyloid β-protein (Aβ) have emerged as key players in the etiology and potential treatment of Alzheimers disease (AD), but it is unlikely that all such proteases have been identified. To discover new A-degrading proteases (AβDPs), we conducted an unbiased, genome-scale, functional cDNA screen designed to identify proteases capable of lowering net Aβ levels produced by cells, which were subsequently characterized for Aβ-degrading activity using an array of downstream assays. Results: The top hit emerging from the screen was β-site amyloid precursor protein-cleaving enzyme 2 (BACE2), a rather unexpected finding given the well-established role of its close homolog, BACE1, in the production of Aβ. BACE2 is known to be capable of lowering Aβ levels via non-amyloidogenic processing of APP. However, in vitro, BACE2 was also found to be a particularly avid ADP, with a catalytic efficiency exceeding all known AβDPs except insulin-degrading enzyme (IDE). BACE1 was also found to degrade Aβ, albeit ∼150-fold less efficiently than BACE2. A is cleaved by BACE2 at three peptide bondsPhe19-Phe20, Phe20-Ala21, and Leu34-Met35with the latter cleavage site being the initial and principal one. BACE2 overexpression in cultured cells was found to lower net A levels to a greater extent than multiple, well-established AβDPs, including neprilysin (NEP) and endothelin-converting enzyme-1 (ECE1), while showing comparable effectiveness to IDE. Conclusions: This study identifies a new functional role for BACE2 as a potent AβDP. Based on its high catalytic efficiency, its ability to degrade A intracellularly, and other characteristics, BACE2 represents a particulary strong therapeutic candidate for the treatment or prevention of AD.

KW - β-site APP-cleaving enzyme-1

KW - -site APP-cleaving enzyme-2

KW - Alzheimer disease

KW - Amyloid-β-protein

KW - Functional screen

KW - Gene therapy

KW - Protease

KW - Proteolytic degradation

UR - http://www.scopus.com/inward/record.url?scp=84867583311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867583311&partnerID=8YFLogxK

U2 - 10.1186/1750-1326-7-46

DO - 10.1186/1750-1326-7-46

M3 - Article

VL - 7

JO - Molecular Neurodegeneration

JF - Molecular Neurodegeneration

SN - 1750-1326

IS - 1

M1 - 46

ER -